4D Molecular Therapeutics announced positive two-year results from its PRISM Phase 2b trial for 4D-150, a one-shot eye therapy for wet age-related macular degeneration. The data showed significant reductions in treatment burden and a favorable safety profile, positioning the drug well for its ongoing Phase 3 trials and potentially transforming wet AMD treatment.
4D Molecular Therapeutics (FDMT) released compelling two-year data for its 4D-150 therapy in wet AMD, demonstrating a substantial 78% reduction in treatment burden compared to standard care, with an even greater 87% reduction in recently diagnosed patients. This long-term efficacy and strong safety profile, with minimal adverse events, significantly de-risks the ongoing Phase 3 trials (4FRONT-1 and 4FRONT-2). For traders, this positive data provides a strong bullish signal for FDMT, as successful Phase 3 outcomes could lead to market approval and a significant competitive advantage in the wet AMD market, which is currently dominated by therapies requiring frequent injections. The long-term implications are a potential shift in treatment paradigms for wet AMD, offering patients a more convenient and effective option.